FdaApplication
NDA 212327
Identifiers
- fda_app_no: NDA212327
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL-MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2019-08-16 |
Revenue by product
INREBIC
| Period | Revenue |
|---|---|
| Q4 2023 | $29.0M |
| Q3 2023 | $29.0M |
| Q2 2023 | $27.0M |
| Q1 2023 | $25.0M |
| Q4 2022 | $23.0M |
| Q3 2022 | $21.0M |
| Q2 2022 | $23.0M |
| Q1 2022 | $18.0M |
| Q4 2021 | $20.0M |
| Q3 2021 | $22.0M |
| Q2 2021 | $16.0M |
| Q1 2021 | $16.0M |
| Q4 2020 | $15.0M |
| Q3 2020 | $13.0M |
| Q2 2020 | $15.0M |
| Q1 2020 | $12.0M |
| Q4 2019 | $5.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
| Q1 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| INREBIC | FEDRATINIB HYDROCHLORIDE | EQ 100MG BASE | CAPSULE;ORAL |
1 product